CYP2C19 Point-of-Care Pharmacogenomic EQA Scheme
EMQN CIC’s CYP2C19 EQA scheme is designed to support the accurate and timely identification of CYP2C19 variants in acute clinical settings. This ensures that patients—particularly those presenting with recent ischaemic stroke or transient ischaemic attack (TIA)—receive the most appropriate antiplatelet therapy.
Identifying CYP2C19 poor or intermediate metabolisers enables tailored clopidogrel prescribing, which may improve clinical outcomes and reduce the risk of adverse events.
A First-of-Its-Kind Pilot for POCT Pharmacogenomics
This pilot EQA programme is among the first dedicated to the rapidly growing field of point-of-care pharmacogenomic testing, marking a significant step forward in delivering reliable genomic insights directly at the bedside.
In urgent care environments—where therapeutic decisions must be made within minutes—even minor genotyping errors can result in suboptimal treatment or avoidable harm.
Registration Now Open
Registration for the EMQN CIC CYP2C19 EQA scheme is now open.
To register or request further information, please contact: office@emqn.org